

Study GO40782 Clinical Trial Assay

CAUTION—Investigational Device. Limited by Federal (or United States) law to investigational use.

For performance evaluation only - the results provided in this report are for investigational use only to determine eligibility for GO40782.

STUDY

Partner Name **Roche Pharma**
 Partner Study ID **GO40782**
 FMI Study ID **F1S-BPA-PRO-18-993**

TEST

FMI Test Order # **ORD-0847341-01**
 Test Type **FoundationOne DX1**
 Report Date **16 Jul 2020**

PATIENT

Subject ID **15006-1308**
 Site ID **15006**
 Sex **Male**
 Date of Birth **13MAY1956**
 Diagnosis **Prostate acinar adenocarcinoma**

SPECIMEN

Specimen ID **10022276**
 Sample Type **Slide Deck**
 Site **Lymph Node**
 Collection Date **28MAY2020**
 Received Date **03JUL2020**
 Visit Type **Archival/Pre-Treatment**

Potential Enrollment Eligible Alterations

GENE	ALTERATION
None Detected	

GENOMIC FINDINGS

NOTE: This is a comprehensive list of cancer-related alterations detected in this patient's sample.

GENE	ALTERATION
PTEN	loss
PTEN	A328fs*16
GNAS	R160C
TP53	T253N

GENOMIC SIGNATURES

NOTE: This section includes information for genomic signatures reported in this test.

Biomarker	Result
Tumor Mutational Burden	3.78 mutations-per-megabase
Microsatellite Instability	MS-Stable

VARIANTS OF UNKNOWN SIGNIFICANCE

Note: These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes significance unclear. FMI VUS are included here, in the event that they become clinically meaningful in the future.

GENE	ALTERATION
CALR	amplification
SYK	H506R
CREBBP	D7Y
TSC2	L1137V
PIK3CB	N553I